PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
- Conditions
- Sickle Cell DiseaseVaso-occlusive Pain Episode in Sickle Cell DiseaseVaso-occlusive Crisis
- Interventions
- Drug: PlaceboDrug: Inclacumab
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT04935879
- Locations
- 🇺🇸
UCI Center for clinical research, Orange, California, United States
🇺🇸University of South Alabama Children's and Women's Hospital, Mobile, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 262
- Registration Number
- NCT04930445
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Retrospective Real World Oxbryta® Data Collection and Analysis Study
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 216
- Registration Number
- NCT04930328
- Locations
- 🇺🇸
Rutgers Robert Wood Johnson Medical School Pediatric Clinical Research Center, New Brunswick, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
- Conditions
- Sickle Cell DiseaseVaso-occlusive Pain Episode in Sickle Cell DiseaseVaso-occlusive Crisis
- Interventions
- Drug: PlaceboDrug: Inclacumab
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT04927247
- Locations
- 🇺🇸
University of South Alabama Children's and Women's Hospital, Mobile, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Strada Patient Care Center, Mobile, Alabama, United States
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
- Conditions
- Complicated Intra-abdominal Infection
- Interventions
- Drug: PF-06947386Drug: Metronidazole
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT04927312
- Locations
- 🇯🇵
Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan
🇯🇵Yamagata City Hospital Saiseikan, Yamagata, Japan
🇯🇵National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan
Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT04916769
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults
- Conditions
- Healthy
- Interventions
- Drug: Vupanorsen
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT04916795
- Locations
- 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: PlaceboDrug: Temanogrel
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT04915950
- Locations
- 🇺🇸
UPMC Arthritis and Auotimmune Clinic, Pittsburgh, Pennsylvania, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇬🇧Royal United Hospitals Bath, Bath, United Kingdom
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 258
- Registration Number
- NCT04916509
- Locations
- 🇸🇦
King Abdulaziz Medical City National Guard Hospital Riyahd, Riyadh, Saudi Arabia
🇦🇪Dubai Hospital, Dubai, United Arab Emirates
🇸🇦King Saud University Medical City Riyadh PO BOX 7805, Riyadh, Saudi Arabia
Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
- Conditions
- Renal Impairment
- Interventions
- Drug: PF-07321332/ritonavir
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT04909853
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Miami, Florida, United States